See more : Tekmar Group plc (TGP.L) Income Statement Analysis – Financial Results
Complete financial analysis of Rogers Corporation (ROG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rogers Corporation, a leading company in the Hardware, Equipment & Parts industry within the Technology sector.
You may be interested
- First Helium Inc. (FHELF) Income Statement Analysis – Financial Results
- Universal Health International Group Holding Limited (2211.HK) Income Statement Analysis – Financial Results
- Adamera Minerals Corp. (DDNFF) Income Statement Analysis – Financial Results
- Decarbonization Plus Acquisition Corporation IV (DCRD) Income Statement Analysis – Financial Results
- Summit Midstream Partners, LP (SMLP) Income Statement Analysis – Financial Results
Rogers Corporation (ROG)
About Rogers Corporation
Rogers Corporation designs, develops, manufactures, and sells engineered materials and components worldwide. It operates through Advanced Electronics Solutions (AES), Elastomeric Material Solutions (EMS), and Other segments. The AES segment offers circuit materials, ceramic substrate materials, busbars, and cooling solutions for applications in electric and hybrid electric vehicles (EV/HEV), wireless infrastructure, automotive, telematics and thermal solutions, aerospace and defense, mass transit, clean energy, connected devices, and wired infrastructure markets. This segment sells its products under the curamik, ROLINX, RO4000, RO3000, RT/duroid, CLTE Series, TMM, AD Series, DiClad, CuClad Series, Kappa, COOLSPAN, TC Series, 92ML, IsoClad, MAGTREX, XTremeSpeed RO1200, IM Series, 2929 Bondply, 3001 Bondply Film, and SpeedWave names. The EMS segment provides engineered material solutions, including polyurethane and silicone materials used in cushioning, gasketing, sealing, and vibration management applications; customized silicones used in flex heater and semiconductor thermal applications; and polytetrafluoroethylene and ultra-high molecular weight polyethylene materials used in wire and cable protection, electrical insulation, conduction and shielding, hose and belt protection, vibration management, cushioning, gasketing and sealing, and venting applications. This segment sells its products under the PORON, BISCO, DeWAL, ARLON, eSORBA, Griswold, XRD, Silicone Engineering, and R/bak names. The Other segment provides elastomer components; and elastomer floats for level sensing in fuel tanks, motors, and storage tanks for applications in the general industrial and automotive markets under the ENDUR and NITROPHYL names. Rogers Corporation was founded in 1832 and is headquartered in Chandler, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 908.40M | 971.17M | 932.89M | 802.58M | 898.26M | 879.09M | 821.04M | 656.31M | 641.44M | 610.91M | 537.48M | 498.76M | 553.15M | 379.19M | 291.82M | 365.36M | 431.35M | 454.56M | 356.11M | 365.00M | 243.33M | 219.44M | 216.04M | 248.22M | 247.80M | 216.60M | 189.70M | 141.50M | 140.30M | 133.90M | 123.20M | 172.40M | 182.40M | 190.30M | 174.90M | 162.50M | 145.30M | 128.80M | 125.30M |
| Cost of Revenue | 601.30M | 650.16M | 583.75M | 510.76M | 583.97M | 568.31M | 502.47M | 406.83M | 406.08M | 376.97M | 349.78M | 340.02M | 374.07M | 242.49M | 212.55M | 251.40M | 315.72M | 311.66M | 252.97M | 251.81M | 164.79M | 150.18M | 149.18M | 165.71M | 165.60M | 150.10M | 127.00M | 91.50M | 90.80M | 87.00M | 82.60M | 129.90M | 134.00M | 139.40M | 126.70M | 117.90M | 101.10M | 90.80M | 91.50M |
| Gross Profit | 307.10M | 321.02M | 349.14M | 291.82M | 314.29M | 310.78M | 318.58M | 249.49M | 235.36M | 233.94M | 187.70M | 158.75M | 179.08M | 136.70M | 79.28M | 113.96M | 115.64M | 142.90M | 103.15M | 113.19M | 78.54M | 69.26M | 66.86M | 82.51M | 82.20M | 66.50M | 62.70M | 50.00M | 49.50M | 46.90M | 40.60M | 42.50M | 48.40M | 50.90M | 48.20M | 44.60M | 44.20M | 38.00M | 33.80M |
| Gross Profit Ratio | 33.81% | 33.05% | 37.43% | 36.36% | 34.99% | 35.35% | 38.80% | 38.01% | 36.69% | 38.29% | 34.92% | 31.83% | 32.37% | 36.05% | 27.17% | 31.19% | 26.81% | 31.44% | 28.96% | 31.01% | 32.28% | 31.56% | 30.95% | 33.24% | 33.17% | 30.70% | 33.05% | 35.34% | 35.28% | 35.03% | 32.95% | 24.65% | 26.54% | 26.75% | 27.56% | 27.45% | 30.42% | 29.50% | 26.98% |
| Research & Development | 35.70M | 35.21M | 29.90M | 29.32M | 31.69M | 33.08M | 29.55M | 28.58M | 27.64M | 22.88M | 21.65M | 19.31M | 21.62M | 19.79M | 17.40M | 21.89M | 24.66M | 24.36M | 19.96M | 20.49M | 13.67M | 13.60M | 12.57M | 12.49M | 10.80M | 10.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 216.00M | 215.53M | 190.45M | 180.08M | 165.08M | 160.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -12.80M | 3.30M | 2.70M | 2.20M | 3.60M | 3.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 203.20M | 218.83M | 193.15M | 182.28M | 168.68M | 164.05M | 160.01M | 136.32M | 131.46M | 125.24M | 106.40M | 99.69M | 104.22M | 89.55M | 68.55M | 82.22M | 73.19M | 63.01M | 55.80M | 58.41M | 43.30M | 39.34M | 39.25M | 40.53M | 36.70M | 28.10M | 26.10M | 30.50M | 30.80M | 29.90M | 25.50M | 56.90M | 37.70M | 42.10M | 32.60M | 32.30M | 30.10M | 27.10M | 27.70M |
| Other Expenses | 0.00 | -144.01M | 5.33M | -104.00K | 959.00K | -994.00K | 3.38M | -1.79M | -8.49M | -1.19M | -1.24M | -208.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.40M | 8.40M | 6.60M | 5.80M | 5.70M | 6.70M | 6.70M | 10.90M | 11.70M | 11.20M | 10.60M | 9.60M | 8.60M | 7.30M | 5.90M |
| Operating Expenses | 221.80M | 110.02M | 228.39M | 211.50M | 201.33M | 194.03M | 189.56M | 164.90M | 159.11M | 148.12M | 128.04M | 119.00M | 125.84M | 109.34M | 85.94M | 104.10M | 97.84M | 98.64M | 75.76M | 78.90M | 56.97M | 52.93M | 51.82M | 53.02M | 57.90M | 46.90M | 42.30M | 36.30M | 36.50M | 36.60M | 32.20M | 67.80M | 49.40M | 53.30M | 43.20M | 41.90M | 38.70M | 34.40M | 33.60M |
| Cost & Expenses | 823.10M | 760.18M | 812.13M | 722.26M | 785.29M | 762.34M | 692.03M | 571.73M | 565.19M | 525.09M | 477.83M | 459.02M | 499.91M | 351.83M | 298.49M | 355.50M | 413.56M | 410.30M | 328.73M | 330.71M | 221.76M | 203.11M | 201.00M | 218.73M | 223.50M | 197.00M | 169.30M | 127.80M | 127.30M | 123.60M | 114.80M | 197.70M | 183.40M | 192.70M | 169.90M | 159.80M | 139.80M | 125.20M | 125.10M |
| Interest Income | 1.20M | 685.00K | 541.00K | 939.00K | 1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 184.00K | 377.00K | 2.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.30M | 9.55M | 2.54M | 7.14M | 7.93M | 6.63M | 6.13M | 3.93M | 4.48M | 2.95M | 3.48M | 4.30M | 4.91M | 184.00K | 377.00K | 2.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 51.10M | 45.88M | 43.28M | 71.43M | 51.07M | 50.07M | 44.10M | 37.85M | 34.05M | 26.27M | 26.35M | 27.13M | 26.31M | 16.11M | 17.96M | 18.40M | 25.72M | 19.53M | 16.85M | 18.07M | 13.62M | 13.57M | 13.71M | 12.51M | 10.40M | 8.40M | 6.60M | 5.80M | 5.70M | 6.70M | 6.70M | 10.90M | 11.70M | 11.20M | 10.60M | 9.60M | 8.60M | 7.30M | 5.90M |
| EBITDA | 138.70M | 196.49M | 172.64M | 152.11M | 114.87M | 163.34M | 176.52M | 124.53M | 110.31M | 116.00M | 88.54M | 54.08M | 86.31M | 56.30M | 11.29M | 28.26M | 50.90M | 63.79M | 28.79M | 58.90M | 35.19M | 29.90M | 22.80M | 41.99M | 34.70M | 28.00M | 27.00M | 19.50M | 18.70M | 17.00M | 15.10M | -14.40M | 10.70M | 8.80M | 15.60M | 12.30M | 14.10M | 10.90M | 6.10M |
| EBITDA Ratio | 15.27% | 22.29% | 14.19% | 11.05% | 12.85% | 13.74% | 15.50% | 13.00% | 11.89% | 14.93% | 17.93% | 11.44% | 9.39% | 6.16% | 5.21% | 1.04% | 10.73% | 15.82% | 18.53% | 12.67% | 11.76% | 9.65% | 10.55% | 13.76% | 13.36% | 13.16% | 13.34% | 11.02% | 11.62% | 11.50% | 11.44% | -8.64% | 5.37% | 3.63% | 8.23% | 6.65% | 8.81% | 7.69% | 4.31% |
| Operating Income | 85.30M | 144.43M | 89.10M | 17.23M | 66.29M | 112.71M | 130.78M | 83.85M | 76.26M | 80.43M | 49.28M | 25.66M | 52.80M | 27.36M | -29.57M | 9.86M | 14.26M | 44.26M | 4.74M | 34.29M | 21.57M | 14.17M | 13.05M | 29.48M | 24.30M | 19.60M | 20.40M | 13.70M | 13.00M | 10.30M | 8.40M | -25.30M | -1.00M | -2.40M | 5.00M | 2.70M | 5.50M | 3.60M | 200.00K |
| Operating Income Ratio | 9.39% | 14.87% | 9.55% | 2.15% | 7.38% | 12.82% | 15.93% | 12.78% | 11.89% | 13.17% | 9.17% | 5.15% | 9.55% | 7.21% | -10.13% | 2.70% | 3.30% | 9.74% | 1.33% | 9.39% | 8.86% | 6.46% | 6.04% | 11.88% | 9.81% | 9.05% | 10.75% | 9.68% | 9.27% | 7.69% | 6.82% | -14.68% | -0.55% | -1.26% | 2.86% | 1.66% | 3.79% | 2.80% | 0.16% |
| Total Other Income/Expenses | -9.00M | -4.05M | 9.08M | 1.20M | -11.16M | -2.12M | 3.79M | 1.38M | -10.08M | -17.00K | -395.00K | -26.64M | 1.61M | 12.83M | -14.29M | 15.24M | 10.93M | 14.07M | 7.05M | 6.39M | 13.46M | 10.64M | 7.93M | 8.15M | 1.50M | -400.00K | 1.60M | 3.90M | 2.40M | 400.00K | 1.00M | -2.70M | -2.40M | -1.20M | -2.80M | -1.30M | -600.00K | -1.00M | -1.10M |
| Income Before Tax | 76.30M | 140.38M | 126.28M | 68.53M | 55.13M | 110.59M | 132.93M | 82.28M | 66.17M | 80.41M | 48.89M | 22.65M | 55.09M | 40.19M | -20.15M | 25.11M | 25.19M | 58.33M | 11.79M | 46.78M | 35.03M | 24.81M | 20.98M | 37.63M | 25.80M | 19.20M | 22.00M | 17.60M | 15.40M | 10.70M | 9.40M | -28.00M | -3.40M | -3.60M | 2.20M | 1.40M | 4.90M | 2.60M | -900.00K |
| Income Before Tax Ratio | 8.40% | 14.45% | 13.54% | 8.54% | 6.14% | 12.58% | 16.19% | 12.54% | 10.32% | 13.16% | 9.10% | 4.54% | 9.96% | 10.60% | -6.90% | 6.87% | 5.84% | 12.83% | 3.31% | 12.82% | 14.40% | 11.31% | 9.71% | 15.16% | 10.41% | 8.86% | 11.60% | 12.44% | 10.98% | 7.99% | 7.63% | -16.24% | -1.86% | -1.89% | 1.26% | 0.86% | 3.37% | 2.02% | -0.72% |
| Income Tax Expense | 19.70M | 23.75M | 18.15M | 18.54M | 7.81M | 22.94M | 52.47M | 34.00M | 19.85M | 27.53M | 11.23M | -46.48M | 11.28M | 5.62M | 42.72M | 3.49M | 3.32M | 11.88M | -4.65M | 6.68M | 8.76M | 6.20M | 5.25M | 10.91M | 7.20M | 5.40M | 5.50M | 3.70M | 2.30M | 600.00K | 1.70M | -1.60M | -1.10M | -1.20M | 600.00K | 400.00K | 1.50M | 300.00K | -1.70M |
| Net Income | 56.60M | 116.60M | 108.10M | 49.99M | 47.32M | 87.65M | 80.46M | 48.28M | 46.32M | 52.88M | 37.76M | 68.69M | 37.06M | 34.57M | -62.87M | 26.52M | 22.12M | 46.46M | 16.44M | 40.10M | 26.28M | 18.61M | 15.73M | 26.72M | 18.60M | 13.80M | 16.50M | 13.90M | 13.10M | 10.10M | 6.70M | -32.60M | -2.30M | -2.40M | 1.60M | 1.00M | 3.40M | 2.30M | 800.00K |
| Net Income Ratio | 6.23% | 12.01% | 11.59% | 6.23% | 5.27% | 9.97% | 9.80% | 7.36% | 7.22% | 8.66% | 7.03% | 13.77% | 6.70% | 9.12% | -21.54% | 7.26% | 5.13% | 10.22% | 4.62% | 10.99% | 10.80% | 8.48% | 7.28% | 10.76% | 7.51% | 6.37% | 8.70% | 9.82% | 9.34% | 7.54% | 5.44% | -18.91% | -1.26% | -1.26% | 0.91% | 0.62% | 2.34% | 1.79% | 0.64% |
| EPS | 3.04 | 6.21 | 5.77 | 2.68 | 2.55 | 4.77 | 4.43 | 2.68 | 2.52 | 2.94 | 2.23 | 4.18 | 2.31 | 2.19 | -4.01 | 1.69 | 1.34 | 2.77 | 1.01 | 2.41 | 1.83 | 1.20 | 1.03 | 1.79 | 0.62 | 0.91 | 0.56 | 0.48 | 0.46 | 0.71 | 0.14 | -2.63 | -0.19 | -0.20 | 0.04 | 0.02 | 0.07 | 0.05 | 0.02 |
| EPS Diluted | 3.03 | 6.15 | 5.73 | 2.67 | 2.53 | 4.70 | 4.34 | 2.65 | 2.48 | 2.86 | 2.16 | 4.04 | 2.21 | 2.16 | -4.01 | 1.67 | 1.32 | 2.69 | 0.98 | 2.30 | 1.77 | 1.16 | 0.98 | 1.69 | 0.60 | 0.87 | 0.53 | 0.46 | 0.43 | 0.69 | 0.13 | -2.63 | -0.19 | -0.20 | 0.04 | 0.02 | 0.07 | 0.05 | 0.02 |
| Weighted Avg Shares Out | 18.60M | 18.78M | 18.73M | 18.68M | 18.57M | 18.37M | 18.15M | 17.99M | 18.37M | 18.18M | 17.20M | 16.43M | 16.04M | 15.80M | 15.69M | 15.71M | 16.56M | 16.75M | 16.31M | 16.44M | 16.00M | 15.47M | 15.27M | 14.90M | 30.11M | 15.20M | 15.09M | 14.81M | 14.27M | 14.26M | 12.89M | 12.40M | 12.34M | 12.30M | 12.25M | 12.00M | 11.92M | 11.88M | 11.83M |
| Weighted Avg Shares Out (Dil) | 18.70M | 18.95M | 18.86M | 18.71M | 18.71M | 18.66M | 18.55M | 18.22M | 18.68M | 18.70M | 17.77M | 16.99M | 16.74M | 16.01M | 15.69M | 15.92M | 16.75M | 17.29M | 16.72M | 16.44M | 16.00M | 16.02M | 16.00M | 15.85M | 31.29M | 15.80M | 15.09M | 14.81M | 14.27M | 14.65M | 12.89M | 12.40M | 12.34M | 12.30M | 12.25M | 12.00M | 11.92M | 11.88M | 11.83M |
Rogers Expanding Power Substrate Capacity in China to Meet Growing EV and Renewable Energy Demand
CHANDLER, Arizona--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) (“Rogers”), announced its plan to build a new factory in China to manufacture its curamik® AMB (Active Metal Brazed) and DBC (Direct Bonded Copper) substrates to meet significant demand growth. The first phase of the...
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Vabysmo® (faricimab-svoa) for the...
Rogers Corporation (ROG) Q1 2023 Earnings Call Transcript
Rogers Corporation (NYSE:ROG ) Q1 2023 Results Conference Call April 27, 2023 5:00 PM ET Company Participants Steve Haymore - Director, IR Colin Gouveia - President and CEO Ram Mayampurath - SVP and CFO Conference Call Participants Daniel Moore -...
Rogers Corporation Reports First Quarter 2023 Results
CHANDLER, Ariz.--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) today announced financial results for the first quarter of 2023. “First quarter sales and gross margin exceeded the high end of our guidance as a result of improved market demand and continued execution of our...
Rogers Corporation Reports First Quarter 2023 Results
CHANDLER, Ariz.--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) today announced financial results for the first quarter of 2023. “First quarter sales and gross margin exceeded the high end of our guidance as a result of improved market demand and continued execution of our...
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that post-hoc data indicate treatment with Vabysmo® (faricimab-svoa) led to greater and faster drying of retinal fluid with fewer injections compared to...
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), is announcing three new partnerships focused on improving brain health outcomes. These industry-leading initiatives are designed to quantify and assess the complexity, economic impact...
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone...
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the Phase III IMbrave050 study that show Tecentriq® (atezolizumab) plus Avastin® (bevacizumab) demonstrated a statistically significant improvement in recurrence-free...
Rogers Corporation Welcomes Michael Webb as New Senior Vice President and Chief Administrative Officer
CHANDLER, Ariz.--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) (“Rogers”), announced that Michael Webb has joined the company as Senior Vice President and Chief Administrative Officer. He will be responsible for Global Human Resources and Corporate Development. Mike joins Rogers from Nutrien Ltd, where...
Source: https://incomestatements.info
Category: Stock Reports